Edwards Lifesciences Corp. Q3 Income Climbs

What happened

Edwards Lifesciences reported third-quarter net income of $307.5 million, or $0.53 per share, compared with $291.1 million, or $0.50 per share, a year earlier. Revenue rose 10.4% to $1.715 billion from $1.553 billion. Adjusted earnings were $459.4 million, or $0.80 per share.

Confirmed

Global impact / market context

Higher revenue alongside increased net income indicates the company expanded sales and earned more on a reported basis than a year earlier. If that growth continues, it could support cash available for operations or investment, though the article does not explain the drivers or cash effects.

Analyst inference

The article reports both standard net income and adjusted earnings, which excludes certain items, and these figures differ substantially. Investors comparing performance should distinguish the two measures; the supplied information does not identify the excluded items or provide peer results for judging relative strength.

Analyst inference

What to watch

1. Compare the next reported revenue and net income with this quarter’s figures to see whether sales growth and higher reported earnings continue beyond this period. Analyst inference
2. The company lists full-year earnings-per-share guidance of $2.97 to $3.05 and revenue growth guidance of 10% to 11%; these are expectations, not results. Confirmed
3. Check whether future disclosures explain what drove revenue growth and which items were excluded from adjusted earnings, helping clarify the quality and repeatability of reported gains. Analyst inference

Evidence

• Original source link unavailable